TY - JOUR
T1 - Cardiotoxicities of Novel Therapies in Hematological Malignancies
T2 - Monoclonal Antibodies and Enzyme Inhibitors
AU - Prathivadhi-Bhayankaram, Sruti
AU - Abbasi, Muhannad Aboud
AU - Ismayl, Mahmoud
AU - Marar, Rosalyn I.
AU - Al-Abcha, Abdullah
AU - El-Am, Edward
AU - Ahmad, Ali
AU - Acevedo, Andres Daryanani
AU - Ellauzi, Rama
AU - Villarraga, Hector
AU - Paludo, Jonas
AU - Anavekar, Nandan
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/8
Y1 - 2023/8
N2 - Monoclonal antibodies (mAB) selectively target leukemia surface antigens and work by either blocking cell surface receptors or triggering the target cell's destruction. Similarly, enzyme inhibitors bind to complex molecular platforms and induce downstream mechanisms that trigger cell death. These are used in a variety of hematologic malignancies. Yet, they also elicit severe immune-mediated reactions as biological agents that require careful monitoring. Cardiovascular effects include cardiomyopathy, ventricular dysfunction, cardiac arrest, and acute coronary syndrome. While there have been scattered reviews of mAB and enzyme inhibitors, a consolidated resource regarding their cardiovascular risk profile is lacking. We provide general recommendations for initial screening and serial monitoring based on the literature.
AB - Monoclonal antibodies (mAB) selectively target leukemia surface antigens and work by either blocking cell surface receptors or triggering the target cell's destruction. Similarly, enzyme inhibitors bind to complex molecular platforms and induce downstream mechanisms that trigger cell death. These are used in a variety of hematologic malignancies. Yet, they also elicit severe immune-mediated reactions as biological agents that require careful monitoring. Cardiovascular effects include cardiomyopathy, ventricular dysfunction, cardiac arrest, and acute coronary syndrome. While there have been scattered reviews of mAB and enzyme inhibitors, a consolidated resource regarding their cardiovascular risk profile is lacking. We provide general recommendations for initial screening and serial monitoring based on the literature.
UR - http://www.scopus.com/inward/record.url?scp=85159569866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159569866&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2023.101757
DO - 10.1016/j.cpcardiol.2023.101757
M3 - Review article
C2 - 37094764
AN - SCOPUS:85159569866
SN - 0146-2806
VL - 48
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 8
M1 - 101757
ER -